Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded indication. "TNKase provides a faster and simpler admin ...

All potential acute ischemic stroke patients meeting criteria for the use of IV tPA should be offered treatment. The facts are clear, and all that remains is further provider and patient education.

Intravenous delivered tPA is approved by the FDA for the treatment of acute ischemic stroke. The drug can make a big difference, but only if it is given within a specified time frame (up to four and a ...

Thrombolytic therapy for ischemic stroke with tissue plasminogen activator (tPA) increases the risk of brain hemorrhage. In a Nature Medicine paper, Cheng et al. report that, in rodents ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

Hyperglycemia also adversely affects the ischemic brain by disrupting the blood ... there is decreased reperfusion after tissue plasmogin activator (tPA)-induced recanalization, contributing ...